{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:06:50Z","timestamp":1773335210522,"version":"3.50.1"},"reference-count":101,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Advanced Therapy Medicinal Products (ATMPs) often present substantial clinical uncertainties at the time of reimbursement evaluation, particularly due to the lack of appropriate comparators and the absence of long-term clinical endpoints. This study primarily examined two methodological areas relevant to these challenges: indirect treatment comparisons (ITCs) and surrogate endpoints. In addition, the review was supplemented with an assessment of innovative trial designs to explore how emerging approaches may contribute to evidence generation for ATMPs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A structured literature review was conducted using PubMed and Embase, combining keywords such as \u201cHealth Technology Assessment,\u201d \u201cATMP,\u201d \u201cIndirect Treatment Comparison,\u201d and \u201cSurrogate Endpoint,\u201d supplemented with grey literature searches. European pharmacoeconomic guidelines were analyzed using the ISPOR database and referenced national documents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>By April 2025, 27 ATMPs had received European Medicines Agency approval; 20 relied on single-arm trials, and 19 used surrogate endpoints. Single-arm trials limit direct comparative effectiveness assessment, requiring alternative approaches such as ITCs. Conventional ITCs need a common comparator, which is unavailable in single-arm evidence, while population-adjusted indirect comparisons (PAICs) offer a potential solution but depend on strong assumptions and are sensitive to unmeasured confounding. Guidelines generally accept the use of ITCs when direct comparative evidence is unavailable. However, they provide limited guidance on the separate question of when RCTs should be considered infeasible. Surrogate endpoints are widely used due to curative aims of ATMPs, but their validation typically requires RCT evidence and is highly context-specific. Guideline acceptance criteria for surrogate endpoints vary. Some require robust validation demonstrating a causal relationship, while others allow correlation-based or context-specific justification, particularly when direct evidence is limited or the technology addresses rare or serious conditions. Innovative trial designs may help generate more robust evidence in these challenging contexts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The study highlights the need to refine methods for handling single-arm trials, projecting long-term outcomes, and using surrogate endpoints in ATMP evaluations. While some clinical uncertainty is inevitable, healthcare systems must manage it effectively to ensure timely, equitable access without creating additional barriers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1749386","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:29:16Z","timestamp":1773293356000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Addressing clinical uncertainties in ATMP reimbursement: a review of methodological guidelines and European practice"],"prefix":"10.3389","volume":"17","author":[{"given":"Lotte","family":"Delemarre","sequence":"first","affiliation":[{"name":"KU Leuven Department of Pharmaceutical and Pharmacological Sciences","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[{"name":"KU Leuven Department of Pharmaceutical and Pharmacological Sciences","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Van Dyck","sequence":"additional","affiliation":[{"name":"Healthcare Management Centre, Vlerick Business School","place":["Ghent, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[{"name":"KU Leuven Department of Pharmaceutical and Pharmacological Sciences","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/jrsm.1700","article-title":"Twenty years of network meta-analysis: continuing controversies and recent developments","volume":"15","author":"Ades","year":"2024","journal-title":"Res. Synth. Methods"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e240080","DOI":"10.57264\/cer-2024-0080","article-title":"Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting","volume":"13","author":"Alsdorf","year":"2024","journal-title":"J. Comp. Eff. Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"103711","DOI":"10.1016\/j.critrevonc.2022.103711","article-title":"Validity of event-free survival as a surrogate endpoint in haematological malignancy: review of the literature and health technology assessments","volume":"175","author":"Assouline","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.3324\/haematol.2023.284534","article-title":"Indirect treatment comparisons: how to MAIC it right?","volume":"109","author":"Bachy","year":"2024","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1080\/03007995.2021.1947216","article-title":"Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1","volume":"37","author":"Bischof","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhealeco.2016.12.001","article-title":"The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions","volume":"51","author":"Bognar","year":"2017","journal-title":"J. Health Econ."},{"key":"B9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/bjh.15615","article-title":"Serological normalisation as a surrogate marker for minimal residual disease negativity in multiple myeloma","volume":"185","author":"Campbell","year":"2019","journal-title":"Br. J. Haematol."},{"key":"B49","volume-title":"Indirect treatment comparison user guide","year":"2009"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1016\/j.ymthe.2021.07.009","article-title":"Updating the ethical guidance for gene and cell therapy research participation","volume":"29","author":"Cargill","year":"2021","journal-title":"Mol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jval.2016.10.011","article-title":"Time to review the role of surrogate end points in health policy: state of the art and the way forward","volume":"20","author":"Ciani","year":"2017","journal-title":"Value Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0272989X21994553","article-title":"Validity of surrogate endpoints and their impact on coverage recommendations: a retrospective analysis across international health technology assessment agencies","volume":"41","author":"Ciani","year":"2021","journal-title":"Med. Decis. Mak."},{"key":"B13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/hec.4524","article-title":"Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence","volume":"31","author":"Ciani","year":"2022","journal-title":"Health Econ."},{"key":"B14","doi-asserted-by":"publisher","first-page":"102283","DOI":"10.1016\/j.eclinm.2023.102283","article-title":"A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials","volume":"65","author":"Ciani","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1056\/NEJMsb1901642","article-title":"The magic of randomization versus the myth of real-world evidence","volume":"382","author":"Collins","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41416-020-01050-w","article-title":"A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer","volume":"123","author":"Cooper","year":"2020","journal-title":"Br. J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jval.2019.11.003","article-title":"Critical appraisal of published indirect comparisons and network meta-analyses of competing interventions for multiple myeloma","volume":"23","author":"Cope","year":"2020","journal-title":"Value Health"},{"key":"B18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/pst.1622","article-title":"When is a seamless study desirable? Case studies from different pharmaceutical sponsors","volume":"13","author":"Cuffe","year":"2014","journal-title":"Pharm. Stat."},{"key":"B19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jval.2019.12.008","article-title":"Managed entry agreements: policy analysis from the european perspective","volume":"23","author":"Dabbous","year":"2020","journal-title":"Value Health"},{"key":"B20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40290-022-00456-6","article-title":"Real-world evidence: a primer","volume":"37","author":"Dang","year":"2023","journal-title":"Pharm. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"n2191","DOI":"10.1136\/bmj.n2191","article-title":"Raising the bar for using surrogate endpoints in drug regulation and health technology assessment","volume":"374","author":"Dawoud","year":"2021","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13023-018-0931-2","article-title":"Recommendations for the design of small population clinical trials","volume":"13","author":"Day","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.omtm.2019.01.010","article-title":"EU regulatory pathways for ATMPs: Standard, accelerated and adaptive pathways to marketing authorisation","volume":"13","author":"Detela","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B24","article-title":"Guideline on the use of surrogate endpoints in health technology assessment","year":"2015"},{"key":"B25","article-title":"Methodological guideline for quantitative evidence synthesis: direct and indirect comparisons","volume-title":"CG MSCGoHTAH","year":""},{"key":"B26","article-title":"Methodological guideline for quantitative evidence synthesis: direct and indirect comparisons. Member state coordination group on health technology assessment","year":""},{"key":"B27","unstructured":"CAT quarterly highlights and approved ATMPs May 2025\n          \n          \n          2025"},{"key":"B59","first-page":"121","article-title":"Regulation (EC) No 1394\/2007 of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001\/83\/EC and Regulation (EC) No 726\/2004","year":"2007","journal-title":"J. European Union"},{"key":"B28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","article-title":"Surrogate end points in clinical trials: are we being misled?","volume":"125","author":"Fleming","year":"1996","journal-title":"Ann. Intern Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s41669-021-00311-5","article-title":"Similarities and differences in health technology assessment systems and implications for coverage decisions: evidence from 32 countries","volume":"6","author":"Fontrier","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"B30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials","volume":"375","author":"Ford","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e230046","DOI":"10.57264\/cer-2023-0046","article-title":"Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations","volume":"12","author":"Freitag","year":"2023","journal-title":"J. Comp. Eff. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13023-018-0919-y","article-title":"Recent advances in methodology for clinical trials in small populations: the InSPiRe project","volume":"13","author":"Friede","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40273-023-01334-y","article-title":"Surrogacy and the valuation of ATMPs: taking our place in the evidence generation\/assessment continuum","volume":"42","author":"Gladwell","year":"2024","journal-title":"Pharmacoeconomics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"755052","DOI":"10.3389\/fphar.2021.755052","article-title":"Health technology assessment of advanced therapy medicinal products: Comparison among 3 European countries","volume":"12","author":"Gozzo","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/j.clinthera.2024.11.019","article-title":"A systematic review of challenges and opportunities in the implementation of managed entry agreements for advanced therapy medicinal products","volume":"47","author":"Greco","year":"2025","journal-title":"Clin. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40273-020-00935-1","article-title":"Surrogate endpoints in health technology assessment: an international review of methodological guidelines","volume":"38","author":"Grigore","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"31036","DOI":"10.3402\/jmahp.v4.31036","article-title":"Advanced therapy medicinal products: current and future perspectives","volume":"4","author":"Hanna","year":"2016","journal-title":"J. Mark. Access Health Policy"},{"key":"B40","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1089\/hum.2022.056","article-title":"Methods for extrapolating survival analyses for the economic evaluation of advanced therapy medicinal products","volume":"33","author":"Hardy","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.jval.2021.04.263","article-title":"PCN172 evaluation of real-world evidence (RWE) used within health technology Assessments (HTA) in oncology with pivotal single-arm trials: a comparative study of six HTA agencies","volume":"24","author":"Harricharan","year":"2021","journal-title":"Value Health"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1177\/0962280219826609","article-title":"Creating historical controls using data from a previous line of treatment - two non-standard approaches","volume":"29","author":"Hatswell","year":"2020","journal-title":"Stat. Methods Med. Res."},{"key":"B43","article-title":"Principles of medicinal product assessments and appraisal for reimbursement purposes","year":"2020"},{"key":"B44","article-title":"Guidelines for evaluating the clinical effectiveness of health technologies in Ireland","year":"2018"},{"key":"B45","article-title":"Guidance to submitting companies for completion of new product assessment form","year":"2022"},{"key":"B46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11899-019-0495-9","article-title":"Should overall survival remain an endpoint for multiple myeloma trials?","volume":"14","author":"Holstein","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"773712","DOI":"10.3389\/fphar.2021.773712","article-title":"Methodological characteristics of clinical trials supporting the marketing authorisation of advanced therapies in the european union","volume":"12","author":"Iglesias-Lopez","year":"","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.omtm.2021.11.003","article-title":"Current landscape of clinical development and approval of advanced therapies","volume":"23","author":"Iglesias-Lopez","year":"","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B50","article-title":"Methodological guideline for economic evaluation studies of health technologies","year":"2019"},{"key":"B51","year":"2023","journal-title":"General Methods"},{"key":"B34","volume-title":"General methods","year":"2022"},{"key":"B52","unstructured":"Pharmacoeconomic guidelines around the world\n          \n          \n          2025"},{"key":"B53","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s12325-023-02520-2","article-title":"A critical appraisal of matching-adjusted indirect comparisons in spinal muscular atrophy","volume":"40","author":"Jiang","year":"2023","journal-title":"Adv. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13561-022-00402-x","article-title":"Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European access academy","volume":"12","author":"Julian","year":"2022","journal-title":"Health Econ. Rev."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e240040","DOI":"10.57264\/cer-2024-0040","article-title":"Perceptions of indirect treatment comparisons as an evidence base in oncology decision-making: results of an international survey of health technology assessment and payer decision-makers","volume":"13","author":"Katsoulis","year":"2024","journal-title":"J. Comp. Eff. Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"9802","DOI":"10.1038\/s41467-024-54077-5","article-title":"A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases","volume":"15","author":"Kim-McManus","year":"2024","journal-title":"Nat. Commun."},{"key":"B60","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med. Decis. Mak."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-025-01496-z","article-title":"World's first personalized CRISPR therapy given to baby with genetic disease","author":"Ledford","year":"2025","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.7150\/jca.99427","article-title":"Comparison of the efficacy and safety of Axi-Cel and tisa-Cel based on meta-analysis","volume":"15","author":"Liao","year":"2024","journal-title":"J. Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","article-title":"A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma","volume":"9","author":"Looka","year":"2025","journal-title":"Blood Adv."},{"key":"B65","doi-asserted-by":"publisher","first-page":"8457","DOI":"10.2147\/CMAR.S328058","article-title":"The impasse on overall survival in oncology reimbursement decision-making: how can we resolve this?","volume":"13","author":"Lux","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/jmahp12020006","article-title":"Methods for indirect treatment comparison: results from a systematic literature review","volume":"12","author":"Macabeo","year":"","journal-title":"J. Mark. Access Health Policy"},{"key":"B67","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s41669-023-00455-6","article-title":"The acceptance of indirect treatment comparison methods in oncology by health technology assessment agencies in England, France, Germany, Italy, and Spain","volume":"8","author":"Macabeo","year":"","journal-title":"Pharmacoecon Open"},{"key":"B68","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41591-023-02789-4","article-title":"Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency","volume":"30","author":"Migliavacca","year":"2024","journal-title":"Nat. Med."},{"key":"B69","article-title":"NICE health technology evaluations: the manual","year":"2022"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jval.2021.01.015","article-title":"Use of external comparators for health technology assessment submissions based on single-arm trials","volume":"24","author":"Patel","year":"2021","journal-title":"Value Health"},{"key":"B72","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1017\/S0266462314000592","article-title":"Endpoints for relative effectiveness assessment (REA) of pharmaceuticals","volume":"30","author":"Pavlovic","year":"2014","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B73","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med. Decis. Mak."},{"key":"B74","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s41669-021-00295-2","article-title":"Evaluation of advanced therapy medicinal products by the national institute for health and care excellence (NICE): an updated review","volume":"6","author":"Pinho-Gomes","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"B75","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jval.2019.10.010","article-title":"Association between the use of surrogate measures in pivotal trials and health technology assessment decisions: a retrospective analysis of NICE and CADTH reviews of cancer drugs","volume":"23","author":"Pinto","year":"2020","journal-title":"Value Health"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1056\/NEJMsb2512695","article-title":"FDA's new plausible mechanism pathway","volume":"393","author":"Prasad","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"773629","DOI":"10.3389\/fpubh.2022.773629","article-title":"Gene therapy evidence generation and economic analysis: pragmatic considerations to facilitate fit-for-purpose health technology assessment","volume":"10","author":"Qiu","year":"2022","journal-title":"Front. Public Health"},{"key":"B78","article-title":"2021\/2282 of the european parliament and of the council of 15 December 2021 on health technology assessment and amending directive 2011\/24\/EU","year":"2021"},{"key":"B79","article-title":"2025\/327 of the European parliament and of the council of 11 February 2025 on the European health data space and amending directive 2011\/24\/EU and regulation (EU) 2024\/2847","year":"2025"},{"key":"B81","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2217\/cer-2021-0216","article-title":"How does risdiplam compare with other treatments for types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison","volume":"11","author":"Ribero","year":"2022","journal-title":"J. Comp. Eff. Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1111\/biom.13720","article-title":"Solutions for surrogacy validation with longitudinal outcomes for a gene therapy","volume":"79","author":"Roberts","year":"2023","journal-title":"Biometrics"},{"key":"B83","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1017\/cts.2023.583","article-title":"N-of-1 trials: the epitome of personalized medicine?","volume":"7","author":"Samuel","year":"2023","journal-title":"J. Clin. Transl. Sci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2023.09.004","article-title":"A methodological review of population-adjusted indirect comparisons reveals inconsistent reporting and suggests publication bias","volume":"163","author":"Serret-Larmande","year":"2023","journal-title":"J. Clin. Epidemiol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2217\/cer-2022-0045","article-title":"Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma","volume":"11","author":"Shah","year":"2022","journal-title":"J. Comp. Eff. Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1562861","DOI":"10.1080\/20016689.2018.1562861","article-title":"Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs","volume":"7","author":"Sola-Morales","year":"2019","journal-title":"J. Mark. Access Health Policy"},{"key":"B89","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jval.2020.10.016","article-title":"Prevalence of immature survival data for anti-cancer drugs presented to the national institute for health and care excellence and impact on decision making","volume":"24","author":"Tai","year":"2021","journal-title":"Value Health"},{"key":"B90","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/APO.0000000000000290","article-title":"Retinal dystrophies and the road to treatment: clinical requirements and considerations","volume":"9","author":"Talib","year":"2020","journal-title":"Asia Pac J. Ophthalmol. (Phila)."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jval.2024.05.015","article-title":"A targeted review of worldwide indirect treatment comparison guidelines and best practices","volume":"27","author":"Tanaka","year":"2024","journal-title":"Value Health"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta13080","article-title":"The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK health technology assessment reports","volume":"13","author":"Taylor","year":"2009","journal-title":"Health Technol. Assess."},{"key":"B93","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1177\/0272989X221097081","article-title":"Network meta-analysis on disconnected evidence networks when only aggregate data are available: modified methods to include disconnected trials and single-arm studies while minimizing bias","volume":"42","author":"Thom","year":"2022","journal-title":"Med. Decis. Mak."},{"key":"B94","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/jrsm.1653","article-title":"Population adjusted-indirect comparisons in health technology assessment: a methodological systematic review","volume":"14","author":"Truong","year":"2023","journal-title":"Res. Synth. Methods"},{"key":"B80","volume-title":"Considerations for the design and conduct of externally controlled trials for drug and biological products","year":"2023"},{"key":"B95","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1017\/S0266462309990213","article-title":"Surrogate outcomes in health technology assessment: an international comparison","volume":"25","author":"Velasco Garrido","year":"2009","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jval.2024.05.023","article-title":"Uncertainty in long-term relative effectiveness of medicines in health technology assessment","volume":"27","author":"Versteeg","year":"2024","journal-title":"Value Health"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/mt.2013.175","article-title":"The evolution of nonclinical regulatory science: advanced therapy medicinal products as a paradigm","volume":"21","author":"Vestergaard","year":"2013","journal-title":"Mol. Ther."},{"key":"B102","article-title":"Pharmacotherapeutic assessment methodology, version 3.0","author":"Vinhas","year":"2021"},{"key":"B98","doi-asserted-by":"publisher","first-page":"8309","DOI":"10.3390\/ijerph17228309","article-title":"Application of managed entry agreements for innovative therapies in different settings and combinations: a feasibility analysis","volume":"17","author":"Vreman","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1017\/S0266462325000017","article-title":"Use of surrogate endpoints in health technology assessment: a review of selected NICE technology appraisals in oncology","volume":"41","author":"Wheaton","year":"2025","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B100","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1177\/0272989X231162852","article-title":"Using bayesian evidence synthesis methods to incorporate real-world evidence in surrogate endpoint evaluation","volume":"43","author":"Wheaton","year":"2023","journal-title":"Med. Decis. Mak."},{"key":"B101","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B70","volume-title":"Guideline for economic evaluations in healthcare","year":"2024"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1749386\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:29:20Z","timestamp":1773293360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1749386\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":101,"alternative-id":["10.3389\/fphar.2026.1749386"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1749386","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1749386"}}